Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 14/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | MCL1 | Q07820 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | WRN | Q14191 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6326664 | 0.95 | BLM (0.46) | BLMHTTMCL1SMN1; SMN2KDM4E | |
| SCHEMBL6449271 | 0.90 | LMNA (0.45) | BLMHTTKDM4EKMT2ALMNA | |
| SCHEMBL6326921 | 0.83 | BLM (0.49) | BLMHTTMCL1SMN1; SMN2KDM4E | |
| SCHEMBL6325956 | 0.83 | BLM (0.53) | BLMHTTMCL1SMN1; SMN2KDM4E | |
| SCHEMBL6323159 | 0.81 | BLM (0.57) | BLMHTTMCL1SMN1; SMN2KDM4E | |
| SCHEMBL6329492 | 0.81 | BLM (0.45) | BLMHTTMCL1SMN1; SMN2KDM4E | |
| SCHEMBL6322384 | 0.81 | BLM (0.43) | BLMHTTMCL1SMN1; SMN2KDM4E | |
| SCHEMBL6325025 | 0.80 | RAB9A (0.45) | BLMHTTMCL1SMN1; SMN2KDM4E | |
| SCHEMBL6325733 | 0.80 | BLM (0.46) | BLMHTTMCL1SMN1; SMN2KDM4E | |
| SCHEMBL6325969 | 0.79 | BLM (0.45) | BLMHTTMCL1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | BRISTOL-MYERS SQUIBB CO. | 2005-06-09 | — | — | US | claimed |
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | BRISTOL-MYERS SQUIBB CO. | 2005-06-09 | — | — | US | disclosed |
| US-5684198-A | N-ARYL-2-HYDROXYPROPANAMIDES | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1997-11-04 | — | — | US | disclosed |
| US-5567735-A | CELL POTASSIUM CHANNEL MODULATOR FOR TREATING ASTHMA | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-22 | — | — | US | disclosed |
| US-5565477-A | TREATMENT OF URINARY INCONTINENCE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-15 | — | — | US | disclosed |
| US-5565465-A | TREATMENT OF URINARY INCONTINENCE | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1996-10-15 | — | — | US | disclosed |
| EP-0524781-B1 | Therapeutic amides | ZENECA LTD (GB) | 1996-03-27 | — | — | EP | disclosed |
| US-5474999-A | Useful in treatment of urinary incontinence | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-12-12 | — | — | US | disclosed |
| US-5382598-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-01-17 | — | — | US | disclosed |
| US-5272163-A | Therapeutic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-12-21 | — | — | US | disclosed |
| EP-0524781-A1 | Therapeutic amides | ZENECA LIMITED (GB) | 1993-01-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | SERPINE1, SERPINC1, SERPINB1 | BLM 2929/4885HTT 2797/4885MCL1 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.